×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TENX – tenax therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TENX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/4
07:00 am
tenx
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
Low
Report
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
1/8
02:21 pm
tenx
Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick [Yahoo! Finance]
Medium
Report
Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick [Yahoo! Finance]
1/5
01:40 pm
tenx
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing [Seeking Alpha]
Low
Report
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing [Seeking Alpha]
12/23
04:13 pm
tenx
Tenax Therapeutics (NASDAQ:TENX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Tenax Therapeutics (NASDAQ:TENX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/17
09:16 am
tenx
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Medium
Report
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
12/17
07:19 am
tenx
Tenax Therapeutics (NASDAQ:TENX) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Tenax Therapeutics (NASDAQ:TENX) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/2
03:46 pm
tenx
Tenax Therapeutics (NASDAQ:TENX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Tenax Therapeutics (NASDAQ:TENX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/17
06:20 pm
tenx
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Venrock Healthcare Capital Partners III, L.P.
Low
Report
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Venrock Healthcare Capital Partners III, L.P.
2/17
04:28 pm
tenx
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Point72 Asset Management, L.P.
Low
Report
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Point72 Asset Management, L.P.
2/17
04:28 pm
tenx
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: BIOTECHNOLOGY VALUE FUND L P
Low
Report
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: BIOTECHNOLOGY VALUE FUND L P
2/17
04:09 pm
tenx
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Lind Global Fund II LP
Low
Report
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Lind Global Fund II LP
2/17
04:01 pm
tenx
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: PERCEPTIVE ADVISORS LLC
Low
Report
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: PERCEPTIVE ADVISORS LLC
2/17
09:56 am
tenx
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Dellora Investments LP
Low
Report
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Dellora Investments LP
2/17
08:51 am
tenx
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: RTW INVESTMENTS, LP
Low
Report
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: RTW INVESTMENTS, LP
2/12
01:21 pm
tenx
Form SCHEDULE 13G TENAX THERAPEUTICS, INC. Filed by: MORGAN STANLEY
Low
Report
Form SCHEDULE 13G TENAX THERAPEUTICS, INC. Filed by: MORGAN STANLEY
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/31
Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial
7.4%
1/15 Tenax Therapeutics Inc (NASDAQ: TENX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.8%
6/14 Form 8-K TENAX THERAPEUTICS, INC. For: Jun 13 4.7%
1/22 Tenax Therapeutics Inc (NASDAQ: TENX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 4.3%
8/23 Tenax Therapeutics Provides Clinical Development Update 3.4%
8/30 Form S-8 TENAX THERAPEUTICS, INC. 2.5%
11/8 Form 8-K/A TENAX THERAPEUTICS, INC. For: Jun 13 2.5%
4/29 Form 8-K TENAX THERAPEUTICS, INC. For: Apr 24 2.3%
3/30 Form 10-K TENAX THERAPEUTICS, INC. For: Dec 31 2.1%
2/14 Form SC 13G/A TENAX THERAPEUTICS, INC. Filed by: Iroquois Capital Management, LLC 0.0%
1/15 Tenax Therapeutics Inc (NASDAQ: TENX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.8%
6/14 Form 8-K TENAX THERAPEUTICS, INC. For: Jun 13 4.7%
1/22 Tenax Therapeutics Inc (NASDAQ: TENX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 4.3%
8/23 Tenax Therapeutics Provides Clinical Development Update 3.4%
8/30 Form S-8 TENAX THERAPEUTICS, INC. 2.5%
11/8 Form 8-K/A TENAX THERAPEUTICS, INC. For: Jun 13 2.5%
4/29 Form 8-K TENAX THERAPEUTICS, INC. For: Apr 24 2.3%
3/30 Form 10-K TENAX THERAPEUTICS, INC. For: Dec 31 2.1%
2/14 Form SC 13G/A TENAX THERAPEUTICS, INC. Filed by: Iroquois Capital Management, LLC 0.0%
TOP News Decliners
3/13
Form 8-K TENAX THERAPEUTICS, INC. For: Mar 11
-35.8%
2/29 Tenax Therapeutics Inc (NASDAQ: TENX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -10.8%
1/13 Form 8-K TENAX THERAPEUTICS, INC. For: Jan 13 -7.9%
4/9 Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 “HELP Study” of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction -6.7%
2/21 Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board -5.8%
2/7 Form SC 13G TENAX THERAPEUTICS, INC. Filed by: BlackRock Inc. -5.7%
3/27 Form D TENAX THERAPEUTICS, INC. -5.6%
5/15 Q1/2019 3/31/2019 EPS -0.330 ZacksConsensus N/A ActVsEst N/A - N/A -4.2%
8/14 Q2/2019 6/30/2019 EPS -0.280 ZacksConsensus -0.450 ActVsEst 0.170 - Beat -4.2%
3/23 Form SC 13G TENAX THERAPEUTICS, INC. Filed by: ARMISTICE CAPITAL, LLC -2.0%
2/29 Tenax Therapeutics Inc (NASDAQ: TENX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -10.8%
1/13 Form 8-K TENAX THERAPEUTICS, INC. For: Jan 13 -7.9%
4/9 Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 “HELP Study” of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction -6.7%
2/21 Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board -5.8%
2/7 Form SC 13G TENAX THERAPEUTICS, INC. Filed by: BlackRock Inc. -5.7%
3/27 Form D TENAX THERAPEUTICS, INC. -5.6%
5/15 Q1/2019 3/31/2019 EPS -0.330 ZacksConsensus N/A ActVsEst N/A - N/A -4.2%
8/14 Q2/2019 6/30/2019 EPS -0.280 ZacksConsensus -0.450 ActVsEst 0.170 - Beat -4.2%
3/23 Form SC 13G TENAX THERAPEUTICS, INC. Filed by: ARMISTICE CAPITAL, LLC -2.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: